Grupo de Oncología Experimental

Mariano Barbacid Jefe de Grupo
T +34 912246933 (Ext 4000)
mbarbacid@cnio.es

Investigadores Científicos

Sara García
Carmen Guerra

Becarios Post-doctorales

Juan Carlos López

Becarios Pre-Doctorales

Domingo Acosta
Gonzalo María Aizpurua
Oksana Brehey
Laura De la Puente
Sara Barrambana
Ana María Fernández
Ana Galván
Lucía Lomba
Blanca Rosas
Pian Sun
Elena Zamorano

Técnicos de Laboratorio

Rebeca Barrero
Mª Carmen González
Silvia Jiménez
Alejandra López
Marta San Román
Raquel Villar

Científico Visitante

Matthias Drosten
Mónica Andrea Musteanu

The main thrust of our laboratory is to identify therapeutic strategies against KRAS mutant lung and pancreatic tumours using genetically engineered mouse strains. We recently reported that ablation of KRAS oncogenes induces complete tumour regressions with no signs of tumour resistance. Unfortunately, KRAS inhibitors, either specific for selected mutations or panKRAS inhibitors, only result in partial tumour regressions. Moreover, this limited therapeutic activity is thwarted by the rapid appearance of tumour resistance. Five years ago, we reported that concomitant ablation of two targets involved in KRAS signalling, RAF1 and EGFR, led to the complete disappearance of a limited number of small pancreatic tumours. Yet, most tumours, especially those exhibiting sizes larger than 100 mm³, did not respond to this therapy. We have now identified a third target, STAT3, whose combined ablation with RAF1 and EGFR led to the complete disappearance of all pancreatic tumours regardless of size. More importantly, these mice remained tumour free for up a year. We are now trying to validate this therapeutic strategy using pharmacological approaches with the ultimate goal of translating these results to a clinical scenario.

Publicaciones recientes

Chen D, Lu S, Huang K, Pearson JD, Pacal M, Peidis P, McCurdy S, Yu T, Sangwan M, Nguyen A, Monnier PP, Schramek D, Zhu L, Santamaria D, Barbacid M, Akeno N, Wikenheiser-Brokamp KA, Bremner R. (2025). Cell cycle duration determines oncogenic transformation capacity. Nature 641, 1309-1318. Publicación CNIO.
Fernández-Pisonero I, Lorenzo-Martín LF, Drosten M, Santos E, Barbacid M, Alarcón B, Bustelo XR. (2025). Active R-RAS2/TC21 prevents cell cycle arrest and morphological alterations in mouse embryonic fibroblasts lacking RAS proteins. Oncogene 44, 1905-1921. Publicación CNIO. Open Access
Liaki V, Rosas-Perez B, Guerra C (2025). Unlocking the Genetic Secrets of Pancreatic Cancer: KRAS Allelic Imbalances in Tumor Evolution. Cancers 17, 1226. Publicación CNIO.
Briones AC, Del Estal L, Villa-Gómez C, Bermejo V, Cervera I, Gutiérrez-Huerta P, Montes-Casado M, Ortega S, Barbacid M, Rojo JM, Portolés P. (2025). T Cell-Specific Inactivation of the PI3K p110α Catalytic Subunit: Effect in T Cell Differentiation and Antigen-Specific Responses. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 26, 595. Publicación CNIO.
López-Gil JC, García-Silva S, Ruiz-Cañas L, Navarro D, Palencia-Campos A, Giráldez-Trujillo A, Earl J, Dorado J, Gómez-López G, Monfort-Vengut A, Alcalá S, Gaida MM, García-Mulero S, Cabezas-Sáinz P, Batres-Ramos S, Barreto E, Sánchez-Tomero P, Vallespinós M, Ambler L, Lin ML, Aicher A, García García de Paredes A, de la Pinta C, Sanjuanbenito A, Ruz-Caracuel I, Rodríguez-Garrote M, Guerra C, Carrato A, de Cárcer G, Sánchez L, Nombela-Arrieta C, Espinet E, Sanchez-Arevalo Lobo VJ, Heeschen C, Sainz B Jr. (2024). The Peptidoglycan Recognition Protein 1 confers immune evasive properties on pancreatic cancer stem cells. Gut 73, 1489-1508. Publicación CNIO. Open Access
Sarno F, Tenorio J, Perea S, Medina L, Pazo-Cid R, Juez I, Rocío Garcia-Carbonero, Feliu J, Guillen-Ponce C, Lopez-Casas PP, Guerra C, Duran Y, López-Acosta JF, Alonso C, Esquivell E, Dopazo A, DiAkshinthala D, Muthuswamy S, Lapunzina P, Bockorny B, Hidalgo M (2024). A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: the AVATAR Trial.. Clin Cancer Res (in press). Publicación CNIO.
Fernández-García F, Fernández-Rodríguez A, Fustero-Torre C, Piñeiro-Yáñez E, Wang H, Lechuga CG, Callejas S, Álvarez R, Lopez-García A, Esteban-Burgos L, Salmón M, San Román M, Guerra C, Ambrogio Ch, Drosten M, Santamaria D, Al-Shahrour F, Dopazo A, Barbacid M, Musteanu M (2024). Type I interferon signaling pathway enhances immune-checkpoint inhibition in KRAS mutant lung tumors. Proc Natl Acad Sci USA 121, e2402913121. Publicación CNIO. Open Access
Rodrigo-Faus M, Vincelle-Nieto A, Vidal N, Puente J, Saiz-Pardo M, Lopez-Garcia A, Mendiburu-Eliçabe M, Palao N, Baquero C, Linzoain-Agos P, Cuesta AM, Qu HQ, Hakonarson H, Musteanu M, Reyes-Palomares A, Porras A, Bragado P, Gutierrez-Uzquiza A. (2024). CRISPR/Cas9 screenings unearth protein arginine methyltransferase 7 as a novel essential gene in prostate cancer metastasis. Cancer Lett 588, 216776. Publicación CNIO.
Verstraelen P, Van Remoortel S, De Loose N, Verboven R, Garcia-Diaz Barriga G, Christmann A, Gries M, Bessho S, Li J, Guerra C, Tükel Ç, Martinez SI, Schäfer KH, Timmermans JP, De Vos WH (2024). Serum Amyloid A3 Fuels a Feed-Forward Inflammatory Response to the Bacterial Amyloid Curli in the Enteric Nervous System. Cell Mol Gastroenterol Hepatol 18, 89-104. Publicación CNIO. Open Access
Arora M, Moser J, Hoffman TE, Watts LP, Min M, Musteanu M, Rong Y, Ill CR, Nangia V, Schneider J, Sanclemente M, Lapek J, Nguyen L, Niessen S, Dann S, VanArsdale T, Barbacid M, Miller N, Spencer SL (2023). Rapid adaptation to CDK2 inhibition exposes intrinsic cell-cycle plasticity. Cell 186, 2623-2643. Publicación CNIO. Open Access
Macaya I, Roman M, Welch C, Entrialgo-Cadierno R, Salmon M, Santos A, Feliu I, Kovalski J, Lopez I, Rodriguez-Remirez M, Palomino-Echeverria S, Lonfgren SM, Ferrero M, Calabuig S, Ludwig IA, Lara-Astiaso D, Jantus-Lewintre E, Guruceaga E, Narayanan S, Ponz-Sarvise M, Pineda-Lucena A, Lecanda F, Ruggero D, Khatri P, Santamaria E, Fernandez-Irigoyen J, Ferrer I, Paz-Ares L, Drosten M, Barbacid M, Gil-Bazo I, Vicent S. (2023). Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer. Nat Commun 14, 6332. Publicación CNIO.
Salmón M, Álvarez-Díaz R, Fustero-Torre C, Brehey O, Lechuga CG, Sanclemente M, Fernández-García F, López-García A, Martín-Guijarro MC, Rodríguez-Perales S, Bousquet-Mur E, Morales-Cacho L, Mulero F, Al-Shahrour F, Martínez L, Domínguez O, Caleiras E, Ortega S, Guerra C, Musteanu M, Drosten M, Barbacid M. (2023). Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas.. J Clin Invest 133, e164413. Publicación CNIO. Open Access
Janssen K, Claes F, Van de Velde D, Wehbi VL, Houben B, Lampi Y, Nys M, Khodaparast L, Khodaparast L, Louros N, van der Kant R, Verniers J, Garcia T, Ramakers M, Konstantoulea K, Maragkou K, Duran-Romaña R, Musteanu M, Barbacid M, Scorneaux B, Beirnaert E, Schymkowitz J, Rousseau F (2023). Exploiting the intrinsic misfolding propensity of the KRAS oncoprotein. Proc Natl Acad Sci USA 120, e2214921120. Publicación CNIO. Open Access
Díaz-Alejo JF, April-Monn S, Cihova M, Buocikova V, Villalón López J, Urbanova M, Lechuga CG, Tomas M, Dubovan P, Sánchez BL, Páez SC, Sanjuanbenito A, Lobo E, Romio de la Heras E, Guerra C, de la Pinta C, Barreto Melian E, Rodríguez Garrote M, Carrato A, Ruiz-Cañas L, Sainz B Jr, Torres A, Smolkova B, Earl J. (2023). Establishment of Pancreatic Cancer-Derived Tumor Organoids and Fibroblasts From Fresh Tissue. J Vis Exp 195, e65229. Publicación CNIO.
García-Alonso S, Mesa P, Ovejero LP, Aizpurua G, Lechuga CG, Zarzuela E, Santiveri CM, Sanclemente M, Muñoz J, Musteanu M, Campos-Olivas R, Martínez-Torrecuadrada J, Barbacid M, Montoya G. (2022). Structure of the RAF1-HSP90-CDC37 complex reveals the basis of RAF1 regulation. Mol Cell 82, 3438-3452. Publicación CNIO. Open Access
Diego-González L, Fernández-Carrera A, Igea A, Martínez-Pérez A, Real Oliveira MECD, Gomes AC, Guerra C, Barbacid M, González-Fernández Á, Simón-Vázquez R (2022). Combined Inhibition of FOSL-1 and YAP Using siRNA-Lipoplexes Reduces the Growth of Pancreatic Tumor. Cancers 14, 3102. Publicación CNIO. Open Access
Drosten M, Barbacid M. (2022). KRAS inhibitors: Going non-covalent.. Mol Oncol 16, 3911-3915. Publicación CNIO. Open Access
Paniagua G, Jacob HKC, Brehey O, García-Alonso S, Lechuga CG, Pons T, Musteanu M, Guerra C, Drosten M, Barbacid M. (2022). KSR induces RAS-independent MAPK pathway activation and modulates the efficacy of KRAS inhibitors. Mol Oncol 16, 3066-3081. Publicación CNIO. Open Access
Sanclemente M, Nieto P, Garcia-Alonso S, Fernández-García F, Esteban-Burgos L, Guerra C, Drosten M, Caleiras E, Martinez-Torrecuadrada J, Santamaría D, Musteanu M, Barbacid M (2021). RAF1 kinase activity is dispensable for KRAS/p53 mutant lung tumor progression.. Cancer Cell 39, 294-296. Publicación CNIO. Open Access
Assi M, Achouri Y, Loriot A, Dauguet N, Dahou H, Baldan J, Libert M, Fain JS, Guerra C, Bouwens L, Barbacid M, Lemaigre FP, Jacquemin P (2021). Dynamic Regulation of Expression of KRAS and Its Effectors Determines the Ability to Initiate Tumorigenesis in Pancreatic Acinar Cells. Cancer Res 81, 2679-2689. Publicación CNIO.
Salmón M, Paniagua G, Lechuga CG, Fernández-García F, Zarzuela E, Álvarez-Díaz R, Musteanu M, Guerra C, Caleiras E, Muñoz J, Ortega S, Drosten M, Barbacid M (2021). KRAS4A induces metastatic lung adenocarcinomas in vivo in the absence of the KRAS4B isoform. Proc Natl Acad Sci USA 118, e2023112118. Publicación CNIO. Open Access
Rosigkeit S, Kruchem M, Thies D, Kreft A, Eichler E, Boegel S, Jansky S, Siegl D, Kaps L, Pickert G, Haehnel P, Kindler T, Hartwig UF, Guerra C, Barbacid M, Schuppan D, Bockamp E. (2021). Definitive evidence for Club cells as progenitors for mutant Kras/Trp53-deficient lung cancer. Int J Cancer 149, 1670-1682. Publicación CNIO. Open Access
Drosten M, Barbacid M (2021). Targeting KRAS mutant lung cancer: light at the end of the tunnel.. Mol Oncol (in press). Publicación CNIO. Open Access
Köhler J, Zhao Y, Li J, Gokhale PC, Tiv HL, Knott AR, Wilkens MK, Soroko KM, Lin M, Ambrogio C, Musteanu M, Ogino A, Choi J, Bahcall M, Bertram AA, Chambers ES, Paweletz CP, Bhagwat SV, Manro JR, Tiu RV, Jänne PA (2021). ERK inhibitor LY3214996-based treatment strategies for RAS-driven lung cancer.. Mol Cancer Ther 20, 641-654. Publicación CNIO.
Lechuga CG, Salmón M, Paniagua G, Guerra C, Barbacid M, Drosten M (2021). RASless MEFs as a Tool to Study RAS-Dependent and RAS-Independent Functions. Methods Mol Biol 2262, 335-346. Publicación CNIO.